Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923220 | 0.94 | MAPK1 (0.54) | MAPK1MAOBPDK1PDK2PDK3 | |
| SCHEMBL5923453 | 0.86 | MAPK1 (0.63) | MAPK1MAOBPDK1PDK2PDK3 | |
| SCHEMBL5923099 | 0.85 | MITF (0.47) | MAPK1LMNAMEN1KMT2A | |
| SCHEMBL4981980 | 0.84 | NR1H4 (0.58) | MAPK1MAOBPDK1PDK2PDK3 | |
| SCHEMBL5923340 | 0.84 | MAPT (0.44) | LMNAKMT2AUSP2 | |
| SCHEMBL5923319 | 0.82 | MAPK1 (0.50) | MAPK1MAOBPDK1PDK2PDK3 | |
| SCHEMBL5923526 | 0.81 | MAPK1 (0.57) | MAPK1MAOBPDK1PDK2PDK3 | |
| SCHEMBL5923256 | 0.81 | MAPK1 (0.56) | MAPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL5923213 | 0.80 | VSIR (0.50) | MEN1KMT2A | |
| SCHEMBL4984259 | 0.80 | MEN1 (0.61) | PDK1PDK2PDK3PDK4LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | MAPK1 2055/4885MAOB 358/4885PDK1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.